Osteosarcoma is the most common bone cancer in teenagers and young adults, about 1,000 US cases a year. Chemotherapy (MAP) and surgery cure about two thirds of people whose cancer has not spread, a rate that has barely changed in 30 years. In 2026 the first phase 3 trial in relapsed disease succeeded.
- 130studies open or running
- 4phase 3 trials
- 1,632papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
First phase 3 win at relapseHappened 67% lower risk of growth
Risvutatug rezetecan cut the risk of growth by 67% vs chemotherapy in ARTEMIS-011.
67%: lower risk of growth or death than gemcitabine-docetaxel.
Lenvatinib delayed growth, not deathHappened
Adding lenvatinib to chemotherapy did not extend survival in young people with relapse.
-
6 months
by May 2027
Full ARTEMIS-011 publicationPossible 67% lower risk of growth
Survival data and peer-reviewed results will show whether the benefit lasts.
67%: lower risk of growth or death than gemcitabine-docetaxel.
-
12 months
by Nov 2027
Mifamurtide added to chemotherapyPossible
A French trial of the immune booster mifamurtide in high-risk osteosarcoma finished its main data collection in 2026.
-
3 years
by late 2029
HER2 immunotherapy after lung surgeryLong shot 71.2% alive at 3 years
OST-HER2: 71.2% alive at 3 years vs 45.8% in past patients, needing a randomized test.
71.2%: 3-year survival, vs 45.8% in historical controls.
Antibody-drug conjugates move earlierLong shot
If confirmed, B7-H3 and HER2 drugs could be tested as part of first treatment.
-
5 years
by late 2031
A European platform to test new drugs from diagnosisPossible
FOSTER (530 people, Gustave Roussy) will test multiple new treatments within one trial through 2035.
The research paths
Antibody-drug conjugates
67% lower risk of growthDetails and 1 trialsHide
Targeted chemotherapy carriers aimed at B7-H3 and HER2.
WatchARTEMIS-011 survival; regulatory filings.
Immune treatments
71.2% alive at 3 yearsDetails and 1 trialsHide
Vaccines and immune boosters to prevent relapse after surgery.
WatchMifamurtide and OST-HER2.
New ways to run trials
Details and 1 trialsHide
Platform trials test several drugs at once in this rare cancer.
WatchFOSTER enrollment.
Borrowed from other cancers
From Breast and stomach cancer
Trastuzumab deruxtecan
Phase 2
A HER2 antibody-drug conjugate tested in recurrent osteosarcoma.
From Thyroid and kidney cancer
Lenvatinib
Phase 2
A multi-target pill tested with chemotherapy.
Open to join now
-
From diagnosis, Europe
FOSTER platform trial
Locations and eligibility → -
Recurrent
Trastuzumab deruxtecan
Locations and eligibility → -
Lung spread at diagnosis
Open vs keyhole lung surgery
Locations and eligibility →
See every recruiting Osteosarcoma trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
Knowledge on the way
Not treatments yet: detection, causes and how care is delivered. Mostly NIH-funded.
- AreaQuestionFunded throughNews likely
- Genomics Patient-partnered genomics of rare cancers (Count Me In)Broad Institute · NIH Funded through Aug 2027 News likely 2027
What just happened
ARTEMIS-011: 67% lower risk of growth
ESMO 2026.
OST-HER2: 71.2% 3-year survival
Interim, vs historical controls.
Standard treatment today
- LocalizedMAP chemotherapy (methotrexate, doxorubicin, cisplatin), surgery, then more MAP.
- Spread to the lungsThe same chemotherapy plus surgery to remove lung nodules when possible.
- RelapseSurgery if possible; ifosfamide-based chemotherapy, cabozantinib or regorafenib; clinical trials.
How to read this page, and sourcesHow to read this page, and sources
- Osteosarcoma is rare, so many results come from small or single-arm trials.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Osteosarcoma trials recruiting now →